The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.
NOTE: This Case Evaluation form can also be completed for situations that involve other incretin mimetic drugs which are used as diabetes medications, such as Bydureon, Januvia, and Victoza -- even in there is no Byetta involved.
Diabetes drugs in the incretin mimetic class -- and their manufacturers -- include:
Exenatide (Byetta, Bydureon / injection) -- Amylin, which was acquired by Bristol Myers Squibb (BMS), which co-markets with Astra-Zeneca (AZ);
Liraglutide (Victoza / injection) -- Novo Nordisk;
Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync / tablets) -- Merck;
Saxagliptin (Onglyza, Kombiglyze XR / tablets) -- BMS/AZ;
Alogliptin (Nesina, Kazano, Oseni / tablets) -- Takeda; and,
Linagliptin (Tradjenta, Jentadueto / tablets) -- Boehringer Ingelheim
My Articles About Byetta
Earlier Byetta articles by Tom Lamb on the Drug Injury Watch blog:
Drug Injury Watch: Warnings About Byetta Associated With Risk Of Severe Pancreatitis And Renal Failure
Drug Injury Watch: August 2008: Byetta Associated With Hemorrhagic Pancreatitis And Necrotizing Pancreatitis